Dabrafenib + Trametinib for cancer treatmentz
Dear Oxford Health NHS Foundation Trust,
Please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.
A) Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer
I sincerely thank you for taking the time to answer these questions.
Yours faithfully,
David Elder
Dear David Elder
Thank you for your email requesting information regarding dabrafenib and
trametinib.
We are treating your correspondence as a request for information under the
Freedom of Information Act 2000.
You should normally expect to receive a further reply from us within 20
working days from the day when your request was originally received by
this Department.
The Trust will endeavour to process your request. However, in light of
the national emergency and the Trust prioritising Covid-19 staff time is
at a premium to provide and support clinical services and we may not be
able to provide a timely response.
Kind regards
Carol Embriaco on behalf of
Mark M. Underwood
Head of Information Governance
IM&T Department, Oxford Health NHS Foundation Trust
The White Building, Littlemore MHC, 33 Sandford Road, Oxford, OX4 4XN
direct dial: 01865 902554
email: [1][email address]
From: David Elder <[FOI #874402 email]>
Sent: 29 June 2022 10:27
To: Foiarfi (RNU) Oxford Health <[email address]>
Subject: Freedom of Information request - Dabrafenib + Trametinib for
cancer treatmentz
This email originated from outside of Oxford Health. Please consider
carefully when choosing to open attachments, click links or deal with
unexpected or unusual requests.
Dear Oxford Health NHS Foundation Trust,
Please answer these questions relating to the usage of Dabrafenib +
Trametinib in cancer treatment.
A) Over the previous 6 months, how many patients for the following
diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer
I sincerely thank you for taking the time to answer these questions.
Yours faithfully,
David Elder
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[2][FOI #874402 email]
Is [3][Oxford Health NHS Foundation Trust request email] the wrong address for Freedom of
Information requests to Oxford Health NHS Foundation Trust? If so, please
contact us using this form:
[4]https://www.whatdotheyknow.com/change_re...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[5]https://www.whatdotheyknow.com/help/offi...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
[6]https://www.whatdotheyknow.com/help/ico-...
[7]https://www.whatdotheyknow.com/help/ico-...
Please note that in some cases publication of requests and responses will
be delayed.
If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.
-------------------------------------------------------------------
References
Visible links
1. mailto:[email address]
2. mailto:[FOI #874402 email]
3. mailto:[Oxford Health NHS Foundation Trust request email]
4. https://www.whatdotheyknow.com/change_re...
5. https://www.whatdotheyknow.com/help/offi...
6. https://www.whatdotheyknow.com/help/ico-...
7. https://www.whatdotheyknow.com/help/ico-...
Please find the Trust response attached above.
regards. FoIA Team
On behalf of:
IM&T Services, Oxford Health NHS Foundation Trust, The White Building,
LMHC, Sandford Road, Littlemore, Oxford, OX4 4XN
Email: [1][email address]
From: David Elder <[FOI #874402 email]>
Sent: 29 June 2022 10:27
To: Foiarfi (RNU) Oxford Health <[email address]>
Subject: Freedom of Information request - Dabrafenib + Trametinib for
cancer treatmentz
This email originated from outside of Oxford Health. Please consider
carefully when choosing to open attachments, click links or deal with
unexpected or unusual requests.
Dear Oxford Health NHS Foundation Trust,
Please answer these questions relating to the usage of Dabrafenib +
Trametinib in cancer treatment.
A) Over the previous 6 months, how many patients for the following
diseases have been treated with a combination of Dabrafenib + Trametinib:
i) Metastatic Melanoma
ii) Adjuvant Melanoma
iii) BRAF mutated Lung Cancer
I sincerely thank you for taking the time to answer these questions.
Yours faithfully,
David Elder
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[2][FOI #874402 email]
Is [3][Oxford Health NHS Foundation Trust request email] the wrong address for Freedom of
Information requests to Oxford Health NHS Foundation Trust? If so, please
contact us using this form:
[4]https://www.whatdotheyknow.com/change_re...
Disclaimer: This message and any reply that you make will be published on
the internet. Our privacy and copyright policies:
[5]https://www.whatdotheyknow.com/help/offi...
For more detailed guidance on safely disclosing information, read the
latest advice from the ICO:
[6]https://www.whatdotheyknow.com/help/ico-...
[7]https://www.whatdotheyknow.com/help/ico-...
Please note that in some cases publication of requests and responses will
be delayed.
If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.
-------------------------------------------------------------------
References
Visible links
1. mailto:[email address]
2. mailto:[FOI #874402 email]
3. mailto:[Oxford Health NHS Foundation Trust request email]
4. https://www.whatdotheyknow.com/change_re...
5. https://www.whatdotheyknow.com/help/offi...
6. https://www.whatdotheyknow.com/help/ico-...
7. https://www.whatdotheyknow.com/help/ico-...
We work to defend the right to FOI for everyone
Help us protect your right to hold public authorities to account. Donate and support our work.
Donate Now